U.S. STOCKS ON THE MOVE-Pfizer, Harrow Health, Vallon Pharma
Genprex up on securing approval for dose escalation in lung cancer drug trial
Brief: Genprex Receives Safety Review Committee Approval To Proceed To Final Cohort In Phase 1 Dose Escalation Trial In Advanced Non-Small Cell Lung Cancer
Brief: Genprex Entered Into First Amendment To Exclusive License Agreement With University Of Pittsburgh
U.S. STOCKS ON THE MOVE-Ventyx Biosciences, Skywater Technology, GameStop
U.S. STOCKS ON THE MOVE-CuriosityStream, Coinbase, Ally Financial
U.S. STOCKS ON THE MOVE-Senmiao Tech, U.S. retail stocks, Zinc miners
Genprex up on receiving U.S. patent for cancer treatment
Brief: Genprex Announces U.S. Patent For Reqorsa Immunogene Therapy In Combination With Immune Checkpoint Inhibitors To Treat Cancers
U.S. STOCKS ON THE MOVE-Unity Software, Cardinal Health, Tesla
U.S. STOCKS ON THE MOVE-AEye, Team, Moderna, Snap
U.S. STOCKS ON THE MOVE-Unity Software, Li Auto, Copper Miners
Genprex up as safety panel approves dose escalation in lung cancer study
Brief: Genprex Announces Safety Review Committee Approves Dose Escalation In Acclaim-1 Phase 1/2 Trial Of Reqorsa In Combination With Tagrisso In Non-Small Cell Lung Cancer
Brief: Genprex Announces The Opening For Enrollment Of Its Phase 1/2 Acclaim-2 Clinical Trial Of Reqorsa Immunogene Therapy In Combination With Keytruda To Treat Non-Small Cell Lung Cancer
Brief: Genprex Announces First Patient Dosed In Phase 1/2 Acclaim-1 Clinical Trial Of Reqorsa™ Immunogene Therapy In Combination With Tagrisso® To Treat Non-Small Cell Lung Cancer
Brief: Preclinical Data Show Potential For Use Of Genprex’S Oncoprex® Nanoparticle Delivery System In Treating Colon Cancer
Brief: Genprex To Accelerate Opening Of Acclaim-1 Clinical Trial Sites
U.S. STOCKS ON THE MOVE-Tesla, Container Store, Apple